Clinical Trials Logo

Esophagitis clinical trials

View clinical trials related to Esophagitis.

Filter by:
  • Active, not recruiting  
  • « Prev · Page 2

NCT ID: NCT04394351 Active, not recruiting - Clinical trials for Eosinophilic Esophagitis (EoE)

Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE)

EoE KIDS
Start date: September 1, 2020
Phase: Phase 3
Study type: Interventional

The Primary objective is to demonstrate the efficacy of dupilumab treatment compared with placebo in pediatric patients with active eosinophilic esophagitis (EoE) based on histologic improvement meeting validated histologic criteria. The Secondary objectives are: - To demonstrate the efficacy of dupilumab compared to placebo in pediatric patients with active EoE after 16 weeks of treatment as assessed by endoscopic visual measurements of disease activity using the Eosinophilic Esophagitis-Endoscopic Reference Score (EoE-EREFS) and histologic abnormalities as measured by the EoE Histology Scoring System (EoE-HSS) - To evaluate the safety, tolerability, and immunogenicity of dupilumab treatment for up to 16 weeks in pediatric patients with active EoE - To evaluate the effects of dupilumab on transcriptomic signatures associated with EoE and type 2 inflammation - To study the effects of dupilumab on the type 2 inflammation gene expression signature - To evaluate the concentration-time profile of functional dupilumab in serum in this population - To assess efficacy of long-term (up to 160 weeks) dupilumab treatment - To assess the impact of dupilumab treatment on changes in weight and growth during the extended active period and open-label extension period of the study - To assess safety, tolerability, and immunogenicity of long-term (up to 160 weeks) dupilumab treatment - To evaluate the impact of dupilumab treatment on EoE signs and symptoms

NCT ID: NCT03835663 Active, not recruiting - Gastric Cancer Clinical Trials

The Bacterial Composition of the Stomach in Reflux Disease

Start date: June 4, 2018
Phase:
Study type: Observational

Gastric and oesophageal (OG) cancer associated with poor long term outcome as overall less than 25% of patients survive for more than 5 years due to late recognition of the disease. Growing evidence suggests an important role for bacteria in OG cancer and gastro esophageal reflux disease (GORD) development. About 1 in 10 people suffer from GORD and this one of the most common conditions leading to gastric and oesophageal cancer. In GORD surgical therapy is the most successful preventing cancer but around 85% of patient experience complications afterwards. Acid suppressing medications are reducing the risk of oesophageal cancer but equally increasing the risk of gastric cancer. They also shorten patients' life expectancy and often fail to provide relief. Analysis of stool samples of patients with GORD demonstrated different gut bacterial compositions to normal and rather resembled the one found in cancer. There is a clear need to improve the outcome of OG cancer. This could be achieved by identifying bacteria responsible for cancer development in gastric tissue, gastric content and saliva and potentially eliminate them hence avoid the development of cancer.

NCT ID: NCT03822325 Active, not recruiting - Clinical trials for Eosinophilic Esophagitis

Inflammatory Mediators as Potential Non-Invasive Biomarkers in Subjects With Eosinophilic Esophagitis

Start date: February 2011
Phase:
Study type: Observational [Patient Registry]

The investigators seek to assess esophageal inflammation or lack of it in response to treatment with a novel non-invasive method that would measure eosinophil-associated inflammatory mediators in the blood and urine to determine the presence of active Eosinophilic Esophagitis. For these purposes, the investigators will correlate esophageal inflammatory mediators measured in blood and urine with histological findings identified on esophageal mucosal biopsies. Additionally, biopsies associated mediators will be assessed relative to clinical phenotype and outcome.

NCT ID: NCT02202590 Active, not recruiting - Clinical trials for Eosinophilic Esophagitis

Using Spectrally Encoded Confocal Microscopy (SECM) to Image the Esophagus

Start date: October 2013
Phase: N/A
Study type: Interventional

The goal of this study is to test the feasibility and the tolerability of a tethered spectrally encoded confocal microscopy (SECM) capsule and to use it to image the esophagus.

NCT ID: NCT02008903 Active, not recruiting - Clinical trials for Eosinophilic Esophagitis

Esophageal String Test in Eosinophilic Esophagitis

Start date: January 2009
Phase:
Study type: Observational

The overall goal of this study is to develop a novel minimally invasive device, the Esophageal String Test (EST) to monitor esophageal inflammation during treatment of the rare disease Eosinophilic Esophagitis (EoE) in a safe and efficacious manner. This study is broken down into 2 specific aims: Specific Aim 1: Identify the EoE Biomarker Panel (EBP) that will improve the sensitivity and specificity of the EST for documenting esophageal inflammation in a 1-hour time point. Specific Aim 2: Validate the ability of the EST EBP to monitor therapeutic efficacy in a 1-hour sampling time. Funding Source - FDA OOPD

NCT ID: NCT01988285 Active, not recruiting - Clinical trials for Eosinophilic Esophagitis

Risk Factors and Biomarkers for Diagnosis and Treatment of EoE

Start date: July 2011
Phase:
Study type: Observational

Purpose: To validate our previously developed model of risk factors for diagnosis of eosinophilic esophagitis (EoE), and to assess the utility of serum levels of biomarkers in diagnosis and monitoring of treatment of EoE. Participants: Up to a total of 800 participants (approximately 400 with EoE and 400 without EoE) who are referred for upper endoscopy. Procedures: This is a prospective cohort study. Patients will be compared with newly diagnosed EoE to non-EoE controls, obtain baseline measures, reassess EoE patients after treatment, and also reassess untreated controls. Data collection will include questionnaire results, blood collection, and tissue collection (esophageal biopsies performed during upper endoscopy per pre-specified protocol). Blood will be analyzed for the presence of the candidate biomarkers. Patients will be compared with newly diagnosed EoE to non-EoE controls, obtain baseline measures, reassess EoE patients after treatment, and also reassess untreated controls. Data collection will include questionnaire results, blood collection, possible saliva collection, possible urine collection, and tissue collection (esophageal biopsies performed during upper endoscopy per pre-specified protocol). Blood will be analyzed for the presence of the candidate biomarkers, including eotaxin-3 and IL-13.

NCT ID: NCT01921686 Active, not recruiting - Clinical trials for Gastroesophageal Reflux Disease

Morphological Markers of Gastroesophageal Reflux Disease (GERD)

Start date: March 2013
Phase:
Study type: Observational

The purpose of this project is to learn more about a new and promising way to diagnose acid reflux disease using a very high-powered microscope. This special microscope provides much finer detail than typical microscopes previously used for diagnosing reflux, and may help doctors to better identify children with acid reflux.